Long-Term Effectiveness and Safety of Bimekizumab in Patients with Moderate to Severe Hidradenitis Suppurativa Under Real Clinical Practice Conditions: The Importance of Combined Treatment in Hurley III Patients and Potential Factors Associated with

Bimekizumab shows sustained clinical effectiveness and a manageable safety profile for moderate-to-severe HS in real-world practice up to 48 weeks. In our setting, the combination of medical and surgical treatment is frequently used and may contribute to improved effectiveness, particularly in patients with extensive structural damage.

Authors

Institutions

Publication Details

Journal
Dermatology and Therapy
Published
2025-08-27
DOI
https://doi.org/10.1007/s13555-025-01521-z
Citations
1
Primary Topic
Hidradenitis Suppurativa and Treatments
Type
article
Field-Weighted Citation Impact
2.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Long-Term Effectiveness and Safety of Bimekizumab in Patients with Moderate to Severe Hidradenitis Suppurativa Under Real Clinical Practice Conditions: The Importance of Combined Treatment in Hurley III Patients and Potential Factors Associated with

Antonio Sahuquillo‐Torralba, D. Jiménez‐Gallo, Rafael Botella‐Estrada, Pablo Fernández‐Crehuet et al.
1 citations
Dermatology and Therapy
Hidradenitis Suppurativa and Treatments
2.00
article

Long-Term Effectiveness and Safety of Bimekizumab in Patients with Moderate to Severe Hidradenitis Suppurativa Under Real Clinical Practice Conditions: The Importance of Combined Treatment in Hurley III Patients and Potential Factors Associated with

Antonio Sahuquillo‐Torralba, D. Jiménez‐Gallo, Rafael Botella‐Estrada, Pablo Fernández‐Crehuet, Gemma Martín‐Ezquerra, Alberto Soto‐Moreno, Eva Vilarrasa, Irene Sánchez‐Gutiérrez, Patricia Garbayo‐Salmons, Antonio Martorell, Fernando Alfageme, Laura Mahiques-Santos, Martí Pons Benavent, Alejandro Molina‐Leyva, Begoña Escutia‐Muñoz, Miguel Mansilla‐Polo, Rafael Fayos‐Gregori, R Alcalá-García, Carmen García‐Moronta, Lucía Aguilar-González
article en
1 citations

Abstract

Bimekizumab shows sustained clinical effectiveness and a manageable safety profile for moderate-to-severe HS in real-world practice up to 48 weeks. In our setting, the combination of medical and surgical treatment is frequently used and may contribute to improved effectiveness, particularly in patients with extensive structural damage.

Dermatology and TherapyVol. 15(11)
Universitat de València (ES), Hospital de Sant Pau (ES), Hospital Universitari i Politècnic La Fe (ES), Hospital Universitario Puerta de Hierro Majadahonda (ES), Hospital Universitario Virgen de las Nieves (ES), Hospital de Manises (ES), Hospital Universitario Reina Sofía (ES), Hospital de Sabadell (ES), Hospital General Universitari de Castelló (ES), Hospital Del Mar (ES), Hospital de Sagunto (ES), Hospital Universitario Puerta del Mar (ES), Hospital Virgen de los Lirios (ES), Instituto de Investigación Sanitaria La Fe (ES)
Good health and well-being
Openalex Percentile: Top 12%
Hidradenitis Suppurativa and Treatments
2.00
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.